AGILON HEALTH (AGL)
Health Care · Medicare Advantage and value-based care platform / primary care risk organization · NYSE
Agilon empowers primary care physicians to take financial and clinical risk for managing total healthcare costs under Medicare capitation, using technology and data to drive quality and profitability.
What AGILON HEALTH does
Agilon Health operates a platform that empowers primary care physicians to manage total healthcare needs under a Medicare-centric, globally capitated payment model. The company forms risk-bearing entities in local geographies that contract with payors (primarily Medicare Advantage) to manage attributed patient populations, partnering long-term with anchor physician groups and independent practice associations. As of December 31, 2025, the platform served approximately 511,000 MA members and 114,000 Medicare fee-for-service beneficiaries across 28 anchor physician groups and 30 geographies. Agilon provides integrated technology, operational infrastructure, and capital to transition physicians to a Total Care Model focused on quality improvement and cost reduction.
Themes: Primary care transformation / physician enablement, Medicare Advantage risk contracting, Value-based care / global capitation, Healthcare cost and quality management, ACO / Accountable Care Organizations
Fundamentals
- Price$96.58 as of 2026-08-21 close
- Market cap$1.6B as of 2026-08-21
- 1-year return+214.1% 2025-08-21 close $30.75 → 2026-08-21 close $96.58
- P/En/a negative earnings
- Net margin-3.9% as of 2026-08-24
- Gross margin+3.8% as of 2026-08-24
- ROE-110.3% as of 2026-08-24
- Debt / equity0.13 as of 2026-08-24
- Revenue growth (YoY)+0.3% as of 2026-08-24
- Revenue CAGR (3y)+35.4% SEC XBRL
- Beta2.99 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How AGL compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AGILON HEALTH looks technically
AGILON HEALTH (AGL) is trading 107.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 67 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 8 trading days ago. It is 27.4% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move.
Trend
7
| Distance from the 200-day | it is trading 107.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +107.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $106.08 | $106.08 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $46.59 | $46.59 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 67 trading days ago — a "golden cross", a bullish long-term signal | 67 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 13.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($85.90 to $114.32) — its "stochastic" reading is 38 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 37.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $133.04 | $133.04 |
|---|---|---|
| From the 52-week high | it is 27.4% below its 52-week high (its highest price of the past year) | -27.4% |
| Above the 52-week low | it is 1191.2% above its 52-week low (its lowest price of the past year) | +1,191% |
| Below the 52-week high | it is 27.4% below its highest point of the past year | 27.4% |
| Since a 20-day breakout | it made a new 20-day low about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 26 trading days ago | 26 sessions |
| All-time high | its highest closing price on record is $1120.75 (set on 2021-06-18) | $1120.75 |
| Given back of the 52-week move | over the past year its closes ranged ($7.91 to $129.84), and it has given back roughly a quarter of its rise from last year’s low — 27% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $50.59 to $54.49. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 27.3% |
| From the all-time high | it is 91.4% below its all-time high | -91.4% |
| Nearest price level | it is trading 3.2% above a support level at $93.50 — a price it turned at twice since 2025-01-30, most recently on 2026-06-25. Since 2024-08-21 it has 8 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.2% |
| All-time low | its lowest closing price on record is $7.48 (set on 2026-03-31) | $7.48 |
| Above the all-time low | it is 1191.2% above its all-time low | +1,191% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move | 5th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $9.12 between its high and its low — about 9.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $9.12 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $84.58 and $104.23 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $84.58 – $94.41 – $104.23 |
| Typical daily range (% of price) | its price moves about 9.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.4% |
| Stretch from the 200-day average | it is trading 5.5 daily ranges above its 200-day average price (107.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.3% since the prior reading | +4.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.13 toward buy |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.5% |
|---|---|---|
| Open gap | it gapped 6.7% below the previous close 11 sessions ago and has not traded back through the level it left behind at 107.85 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.7% |
| Gap filled | a 3.3% gap down opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 25.5 percentage points (the stock lost 23.2% while the market gained 2.3%) | -25.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.8 percentage points (the stock gained 19.9% while the market gained 3.1%) | +16.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 770.9 percentage points (the stock gained 782.0% while the market gained 11.1%) | +770.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 193.6 percentage points (the stock gained 214.1% while the market gained 20.5%) | +193.6% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 37.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 69% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $57.21 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +68.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $95.05 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +1.6% |
Price levels it has turned at before
AGL last closed at $96.58 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $93.50 | Support | 3.2% below the last close | turned there twice · 2025-01-30 to 2026-06-25 |
| $101.25 | Resistance | 4.8% above the last close | turned there twice · 2024-09-30 to 2025-02-26 |
| $90.24 | Support | 6.6% below the last close | turned there twice · 2024-10-15 to 2026-05-18 |
| $104.57 | Resistance | 8.3% above the last close | turned there twice · 2024-09-19 to 2026-07-07 |
| $79.78 | Support | 17.4% below the last close | turned there four times · 2024-11-06 to 2026-06-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.56 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$115.08 range $85.00 – $146.00; median $115.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AGL
- Consensus EPS estimate-$0.8587 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory and reimbursement risk: Dependence on Medicare Advantage and CMS payment models (ACO REACH, MSSP); changes in capitation rates, coverage policies, or payor willingness to enter global risk arrangements could significantly impact revenue and profitability.","Stock delisting risk: The company received NYSE noncompliance notice in November 2025 for failing the $1.00 minimum share price requirement and is pursuing a reverse stock split for cure; delisting would adversely impact trading liquidity and market price.","Medical claims and operational leverage risk: Medical services expenses represent the largest component of costs; significant adverse medical loss ratios or underwriting losses in risk-bearing entities could materially impair earnings, evidenced by unprofitability and accumulated deficit of ~$1.93 billion as of March 31, 2026."]
What changed in the latest 10-Q
AI-assisted comparison of AGL's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'our management transition' in the forward-looking statements disclosure (newer filing, 2026-05-06)
- Added bullet point: 'our use of algorithms, artificial intelligence, and machine learning in our business and challenges with properly managing the development and use of these technologies' (newer filing, 2026-05-06)
- Added bullet point: 'non-compliance with the New York Stock Exchange could result in a delisting of our securities' (newer filing, 2026-05-06)
- Reworded:
- Changed reference to 10-K year from 'December 31, 2024' (older filing, 2025-11-04) to 'December 31, 2025' (newer filing, 2026-05-06)
- Modified risk factor language from 'our use of artificial intelligence and machine learning in our business' (older filing, 2025-11-04) to 'our use of algorithms, artificial intelligence, and machine learning in our business' (newer filing, 2026-05-06) - added 'algorithms'
- Changed management transition risk from 'risks related to management transitions, including the search for a permanent Chief Executive Officer, and our ability to effectively manage leadership changes' (older filing, 2025-11-04) to 'risks related to management transitions, including the transition to our new Chief Executive Officer, and our ability to effectively manage leadership changes' (newer filing, 2026-05-06)
- Notes:
- Both filings appear truncated at the end of the MD&A section; full comparison may be incomplete
- Line number references differ between filings (page 21-22 in newer vs. page 23-24 in older), indicating potential formatting differences
Risk Factors
- Added:
- Newer filing (2026-05-06) shows 'Restricted cash and equivalents' of $71,579 thousand as of March 31, 2026, whereas older filing (2025-11-04) showed $0 as of September 30, 2025
- Newer filing includes 'Property, equipment, and capitalized software, net' as line item, whereas older filing separately listed 'Property and equipment, net' and 'Goodwill'
- Newer filing (2026-05-06) reports 16,606 thousand shares outstanding; older filing (2025-11-04) reports 414,570 thousand shares outstanding, indicating a stock split or reverse stock split between filings
- Newer filing shows profitable three-month period ending March 31, 2026 with net income of $48,916 thousand; older filing shows loss of $110,207 thousand for three months ended September 30, 2025
- Newer filing reports income from operations of $3,997 thousand for Q1 2026; older filing reported loss from operations of $131,274 thousand for Q3 2025
- Newer filing VIE disclosures state 'total assets of the Company's consolidated VIEs totaling $1.06 billion' for March 31, 2026; older filing states 'total assets that can only be used to settle obligations...totaling $1.10 billion' for September 30, 2025
- Newer filing shows lower accumulated deficit of $1,929,408 thousand as of March 31, 2026 compared to $1,789,442 thousand as of September 30, 2025 in older filing
- Removed:
- Older filing (2025-11-04) included 'Goodwill' line item of $24,133 thousand; newer filing (2026-05-06) does not separately show goodwill
- Older filing included 'Noncontrolling interests' column in stockholders' equity table for September 30, 2024; newer filing does not include this column
- Older filing presented nine-months year-to-date comparisons; newer filing only presents three-month period ended March 31, 2026
- Reworded:
- Newer filing (2026-05-06) describes VIE disclosure with simplified language: 'total assets of the Company's consolidated VIEs' versus older filing's (2025-11-04) more detailed: 'total assets that can only be used to settle obligations of the Company's consolidated VIEs'
- Newer filing lists 'Depreciation and amortization' separately in expenses; older filing structure appears consistent but newer filing integrates capitalized software into asset line item
- Newer filing references 'Note 12' for VIE details; older filing references 'Note 14' for VIE details
- Notes:
- The significant difference in share counts (16,606 vs 414,570 thousand) between filings suggests a major capital restructuring (likely stock split) that affects all per-share metrics; the financial data may not be directly comparable without adjusting for this structural change
- The older filing covers nine-month and quarterly periods ending September 30, while the newer filing covers only a three-month period ending March 31; period lengths differ materially
- Text appears truncated at end of both filings; full Risk Factors sections and complete financial statement notes are not provided for comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AGL — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AGL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,290,504
- Reported value $10,207,884
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AGL had 872,239 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AGL had 5.19% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.67 days to cover at the same settlement.
- Reported short interest (shares) 872,239
- Short interest (% of shares outstanding) 5.19%
- Prior settlement (shares) 859,438
- Reported change 1.49%
- Days to cover (reported) 2.67
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Humana (HUM)
- UnitedHealth Group / Optum (UNH)
- CVS Health / Aetna (CVS)
- Elevance Health / Anthem (ELV)
- Oak Street Health
- Contigo Health
- Privia Health (PRVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AGL vs…
Frequently asked questions
What does AGILON HEALTH (AGL) do?
Agilon Health operates a platform that empowers primary care physicians to manage total healthcare needs under a Medicare-centric, globally capitated payment model. The company forms risk-bearing entities in local geographies that contract with payors (primarily Medicare Advantage) to manage attributed patient populations, partnering long-term with anchor physician groups and independent practice associations.
What sector is AGILON HEALTH (AGL) in?
AGILON HEALTH (AGL) is classified in the Health Care sector. Its industry is Medicare Advantage and value-based care platform / primary care risk organization. It trades on NYSE.
Who are AGILON HEALTH's (AGL) competitors?
Notable peers of AGILON HEALTH (AGL) include Humana, UnitedHealth Group / Optum, CVS Health / Aetna, Elevance Health / Anthem and Oak Street Health. This peer set is informational only — not financial advice.
Is AGILON HEALTH (AGL) overbought or oversold right now?
AGILON HEALTH (AGL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AGL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.